Alto Neuroscience, Inc. (ANRO) Stock Score, Valuation & Financial Research

Alto Neuroscience, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANRO

Alto Neuroscience, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 25.53. These figures are a research snapshot, not a buy or sell recommendation.

What Alto Neuroscience, Inc. does

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Alto Neuroscience is a clinical-stage biopharmaceutical company that focuses on developing precision medicines for neuropsychiatric conditions. The company utilizes a proprietary neurobiology platform to identify biomarkers that help match patients to specific drug candidates, aiming to improve clinical trial success rates and treatment outcomes.

Products and services

  • The company is developing a pipeline of drug candidates including ALTO-100, ALTO-202, ALTO-203, and ALTO-207, which are currently in various stages of clinical development for conditions such as major depressive disorder and schizophrenia.

Customer types

Patients with neuropsychiatric conditions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and manage related data. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes third-party manufacturers for the production of its drug candidates for clinical use. Source

Business relationships and partnerships

  • Chase Therapeutics Corporation — In May 2025, Alto acquired the ALTO-207 program (formerly CTC-501) from Chase Therapeutics Corporation. Source
  • Cerecor — Alto in-licensed the ALTO-202 compound from Cerecor, which holds rights to a patent originally owned by Merck. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various pharmaceutical and biotechnology companies developing treatments for depression, schizophrenia, and other central nervous system disorders. Source

Business strengths to evaluate

  • Proprietary neurobiology platform for precision psychiatry Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANRO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 25.53
Market capitalization:
895.95M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -84.24M
Free cash flow:
USD -51.79M
Cash:
USD 243.73M
Total debt:
USD 7.05M
EPS:
USD -2.48

What stands out

  • Free cash flow is USD -51.79M, negative for the stored period.
  • The balance sheet shows USD 243.73M of cash versus USD 7.05M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 236.68M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANRO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANRO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANRO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANRO to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ANRO's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ANRO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.